CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs. CRISPR Therapeutics announced promising new ...

In the wake of the germline editing controversy, when Chinese scientist He Jianku illegally edited the embryos of human twins ...

-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% ...

CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.

CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting ...

-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in ...

CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing therapy for sickle cell disease. Reimbursement and access for Casgevy now ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc. (“Scribe”), a genetic medicines company pioneering next-generation in vivo CRISPR-based medicines designed to be safe, durable, and effective ...

As a follow-on to data presented at Keystone Symposia’s Engineering the Genome Conference this past February, Intellia’s ASGCT presentation will focus on process improvements in its CRISPR/Cas9-based ...